A standard drug screen detects five classes of substances: marijuana (THC), cocaine, amphetamines, opioids, and phencyclidine (PCP). That’s the baseline 5-panel test used in most federal and workplace settings. Broader panels add more drug classes, and the specific substances caught depend on which panel your employer, court, or provider orders.
The Standard 5-Panel Test
The 5-panel drug screen is the most common version, required for all U.S. Department of Transportation workers and widely used by private employers. It covers five drug categories, but within each category, the test picks up multiple specific substances:
- Marijuana: THC and its metabolites
- Cocaine: cocaine and its primary breakdown product
- Amphetamines: amphetamine, methamphetamine, MDMA (ecstasy), and MDA
- Opioids: codeine, morphine, heroin (detected as 6-AM), hydrocodone, hydromorphone, oxycodone, and oxymorphone
- PCP: phencyclidine
The opioid category was significantly expanded in 2018. Older panels only caught morphine-based opioids, but the current version includes prescription painkillers like hydrocodone and oxycodone. Federal workplace guidelines now also include fentanyl testing at extremely sensitive cutoff levels (1 ng/mL in urine), making it one of the most tightly screened substances on the panel.
What 10-Panel and 12-Panel Tests Add
Larger panels are common in legal, probation, and clinical settings. A 10-panel test typically includes everything in the 5-panel plus:
- Barbiturates: older sedatives sometimes prescribed for seizures or headaches
- Benzodiazepines: anti-anxiety medications like alprazolam, diazepam, lorazepam, and others
- Methadone
- Propoxyphene: a pain reliever (now withdrawn from the U.S. market but still tested for)
When benzodiazepines show up positive on the initial screen, labs often run expanded confirmation testing that can identify which specific benzodiazepine was used. The confirmation can distinguish between nine or more individual compounds. Some 12-panel tests go further and add substances like buprenorphine or tricyclic antidepressants, though these vary by lab.
What Standard Screens Miss
This is where many people are surprised. Standard drug screens are designed around specific chemical structures, and substances that don’t share those structures can slip through undetected.
Fentanyl was historically one of the most notable blind spots. Because it’s a fully synthetic opioid with a different structure than morphine, older immunoassay panels frequently missed it entirely. Updated federal guidelines now require fentanyl testing at very low thresholds, but not every employer or clinic has adopted the newest panel. If you’re being tested by a private employer using an older kit, fentanyl may or may not be included.
Synthetic cannabinoids like K2 and Spice are not detected by standard urine drug screens. These products are chemically distinct from THC, so the antibodies in a standard test don’t react to them. Detecting synthetic cannabinoids requires a separate, specialized test. The same is true for kratom, GHB, and many designer drugs. If someone ordering your test wants to screen for these, they need to request additional panels specifically.
How the Testing Process Works
Drug screens use a two-step process. The first step is an immunoassay, a rapid chemical test that flags whether a sample is likely positive. It works by using antibodies that bind to drug metabolites in your urine or saliva. This step is fast and inexpensive, but it’s not perfectly accurate.
If the initial screen comes back positive, the sample goes through a second, more precise analysis using mass spectrometry. This confirmatory test can identify the exact substance and its concentration with much higher accuracy. The two-step approach exists specifically because the initial screen can produce false positives. No lab should report a positive result based on the immunoassay alone.
Cutoff Levels That Determine a Positive Result
A drug screen doesn’t simply detect any trace of a substance. Each drug class has a concentration cutoff, measured in nanograms per milliliter (ng/mL). If the amount in your sample falls below that threshold, the result is reported as negative even if trace amounts are technically present.
For urine testing, federal guidelines set the initial screening cutoff for marijuana metabolites at 50 ng/mL, with a lower confirmatory cutoff of 15 ng/mL. Cocaine’s initial cutoff is 150 ng/mL. Amphetamines screen at 500 ng/mL. These thresholds are intentionally set high enough to reduce the chance that passive exposure or tiny residual amounts trigger a positive.
Oral fluid (saliva) testing uses much lower cutoffs because drug concentrations in saliva are naturally lower than in urine. Marijuana screens at 4 ng/mL in oral fluid compared to 50 ng/mL in urine. Amphetamines screen at 50 ng/mL in saliva versus 500 ng/mL in urine. The DOT finalized rules in late 2024 formally integrating oral fluid collection into its testing program, so saliva tests are becoming more common in regulated workplaces.
Common Causes of False Positives
The initial immunoassay screen is prone to cross-reactivity, meaning certain legal medications and supplements can trigger a positive for a drug you never took. Antihistamines, antipsychotics, and antidepressants are among the most common culprits.
For the amphetamine category specifically, several widely used medications can cause a false positive: certain nasal decongestants containing pseudoephedrine, the antidepressant bupropion (commonly prescribed for depression and smoking cessation), the ADHD medication atomoxetine, and even Vicks inhalers. Certain antidepressants like trazodone and fluoxetine have also been implicated.
This is exactly why the confirmatory step matters. Mass spectrometry can distinguish between methamphetamine and a cold medicine. If you’re taking any prescription or over-the-counter medication, disclosing it before the test (or to the medical review officer afterward) helps ensure a false positive gets properly investigated rather than reported as a true positive.
Urine, Saliva, Blood, and Hair
The type of sample collected determines how far back the test can look. Urine is the most common specimen for workplace and legal testing. For most drugs, urine detects use within the past one to four days, though heavy or chronic marijuana use can extend that window to several weeks because THC is stored in fat cells and released slowly.
Oral fluid testing detects drugs for a shorter window, generally 5 to 48 hours after use. It’s harder to cheat on because the collection happens under direct observation, and there’s no opportunity to swap or dilute the sample. Blood testing offers the shortest detection window and is mostly used in emergency rooms or accident investigations where recent impairment is the question. Hair testing has the longest window by far, potentially detecting drug use over the previous 90 days, but it doesn’t capture very recent use within the last week or so.
Detection times vary from person to person. Body fat percentage, metabolic rate, hydration level, how frequently you’ve used the substance, and the dose all influence how quickly your body clears a drug. Two people using the same substance on the same day can test differently a week later.
Specimen Validity Checks
Labs don’t just test for drugs. They also evaluate whether the sample itself is legitimate. Specimen validity testing checks the urine’s creatinine level and pH to determine if it’s consistent with normal human urine. This catches three types of problems: dilution (drinking excessive water to flush your system), substitution (submitting someone else’s urine or a synthetic product), and adulteration (adding chemicals to the sample to destroy drug metabolites). A specimen flagged as invalid or substituted is typically treated the same as a refusal to test in regulated settings.